All Studies All Outcomes

Incidence of Symptoms Associated with Post-Acute Sequelae of SARS-CoV-2 infection in Non-Hospitalized Vaccinated Patients Receiving Nirmatrelvir-Ritonavir

Patel et al., medRxiv, doi:10.1101/2023.04.05.23288196

Apr 2023

Post
Facebook

Source PDF All Studies Meta AnalysisMeta

Download Image

TriNetX retrospective 1,004 paxlovid patients and matched controls, showing lower risk of PASC with treatment.

Confounding by treatment propensity. This study analyzes a population where only a fraction of eligible patients received the treatment. Patients receiving treatment may be more likely to follow other recommendations, more likely to receive additional care, and more likely to use additional treatments that are not tracked in the data (e.g., nasal/oral hygiene1,2, vitamin D3, etc.) — either because the physician recommending paxlovid also recommended them, or because the patient seeking out paxlovid is more likely to be familiar with the efficacy of additional treatments and more likely to take the time to use them. Malden et al. confirm significant bias in the use of paxlovid, showing that treated patients are more likely to be from affluent neighborhoods, be more health-conscious, and have better access to care. Therefore, these kind of studies may overestimate the efficacy of treatments.

Resistance. Variants may be resistant to paxlovid5-8. Use may promote the emergence of variants that weaken host immunity and potentially contribute to long COVID9.

Confounding by contraindication. Hoertel et al. find that over 50% of patients that died had a contraindication for the use of Paxlovid10. Retrospective studies that do not exclude contraindicated patients may significantly overestimate efficacy.

Black box warning. The FDA notes that "severe, life-threatening, and/or fatal adverse reactions due to drug interactions have been reported in patients treated with paxlovid"11.

AKI. Kamo et al. show significantly increased risk of acute kidney injury.

Standard of Care (SOC): SOC for COVID-19 in the study country, the USA, is very poor with very low average efficacy for approved treatments13. Only expensive, high-profit treatments were approved. Low-cost treatments were excluded, reducing the probability of treatment—especially early—due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments.

Important missing comments or errors? Let us know.

risk of PASC, 20.0% lower, RR 0.80, p = 0.01, treatment 1,004, control 1,004, broadly defined, 30-180 days, propensity score matching.

risk of PASC, 25.0% lower, RR 0.75, p = 0.01, treatment 1,004, control 1,004, narrowly defined, 30-180 days, propensity score matching.

risk of PASC, 29.0% lower, RR 0.71, p = 0.01, treatment 1,004, control 1,004, broadly defined, 90-180 days, propensity score matching.

risk of PASC, 26.0% lower, RR 0.74, p = 0.01, treatment 1,004, control 1,004, narrowly defined, 90-180 days, propensity score matching.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

1. c19early.org, c19early.org/p.c19early.org/p.

2. c19early.org (B), c19early.org/ph.c19early.org/ph.

3. c19early.org (C), c19early.org/d.c19early.org/d.

4. Malden et al., Predictors of nirmatrelvir–ritonavir receipt among COVID-19 patients in a large US health system, Scientific Reports, doi:10.1038/s41598-024-57633-7.nature.com, doi.org.

5. Zhou et al., Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system, Science Advances, doi:10.1126/sciadv.add7197.science.org, doi.org.

6. Jochmans et al., The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir, mBio, doi:10.1128/mbio.02815-22.asm.org, doi.org.

7. Lopez et al., SARS-CoV-2 Resistance to Small Molecule Inhibitors, Current Clinical Microbiology Reports, doi:10.1007/s40588-024-00229-6.springer.com, doi.org.

8. Zvornicanin et al., Molecular Mechanisms of Drug Resistance and Compensation in SARS-CoV-2 Main Protease: The Interplay Between E166 and L50, bioRxiv, doi:10.1101/2025.01.24.634813.biorxiv.org, doi.org.

9. Thomas et al., Nirmatrelvir-Resistant Mutations in SARS-CoV-2 Mpro Enhance Host Immune Evasion via Cleavage of NF-κB Essential Modulator, bioRxiv, doi:10.1101/2024.10.18.619137.biorxiv.org, doi.org.

10. Hoertel et al., Prevalence of Contraindications to Nirmatrelvir-Ritonavir Among Hospitalized Patients With COVID-19 at Risk for Progression to Severe Disease, JAMA Network Open, doi:10.1001/jamanetworkopen.2022.42140.jamanetwork.com, doi.org.

11. FDA, Fact sheet for healthcare providers: emergency use authorization for paxlovid, www.fda.gov/media/155050/download.fda.gov.

12. Kamo et al., Association of Antiviral Drugs for the Treatment of COVID-19 With Acute Renal Failure, In Vivo, doi:10.21873/invivo.13637.iiarjournals.org, doi.org.

13. c19early.org (D), c19early.org/soc/usa.html.c19early.org/soc/usa.html.

Patel et al., 6 Apr 2023, retrospective, USA, preprint, mean age 57.2, 17 authors, study period 1 December, 2021 - 17 April, 2022. Contact: sarju.ganatra@lahey.org.

This Paper Paxlovid All

Incidence of Symptoms Associated with Post-Acute Sequelae of SARS-CoV-2 infection in Non-Hospitalized Vaccinated Patients Receiving Nirmatrelvir-Ritonavir 

MD Rushin Patel, MD Sourbha S Dani, MD Sumanth Khadke, MD Javaria Ahmad, MD Jui Shah, MD MPH Neev Mehta, MD Kenneth Wener, MD Daniel P Mcquillen, MD MPH George Abraham, MD Jeremy Faust, MD Jason Maley, MD Smita Patel, MD Janet Mullington, MD Robert M Wachter, MD Anne Mosenthal, MD Paul E Sax, MD Sarju Ganatra

doi:10.1101/2023.04.05.23288196

Assessment of Nirmatrelvir plus ritonavir (NMV-r) in preventing post-acute sequelae of SARS-CoV-2 infection (PASC), based on broad and narrow definitions in non-hospitalized, vaccinated patients between 30-180 days and 90-180 days.

References

Al-Aly, Bowe, Xie, Long COVID after breakthrough SARS-CoV-2 infection, Nat Med

Antonelli, Pujol, Spector, Ourselin, Steves, Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2, Lancet

Bernal, Da Silva, Musungaie, Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients, N Engl J Med

Cdc, Long COVID or Post-COVID Conditions

Elfein, Number of coronavirus (COVID-19) cases, recoveries, and deaths worldwide

Fad, FDA Authorizes New Monoclonal Antibody for Treatment of COVID-19 that Retains Activity Against Omicron Variant

Ganatra, Dani, Ahmad, Oral Nirmatrelvir and Ritonavir in Nonhospitalized Vaccinated Patients With Coronavirus Disease 2019 (COVID-19), Clinical Infectious Diseases

Gottlieb, Vaca, Paredes, Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients, N Engl J Med

Hammond, Leister-Tebbe, Gardner, Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19, N Engl J Med

Organization, Post COVID-19 condition (Long COVID

Rando, Bennett, Byrd, Challenges in defining Long COVID: Striking differences across literature, Electronic Health Records, and patient-reported information, medRxiv

Recover, Explore Research

Rio, Collins, Malani, Long-term Health Consequences of COVID-19, JAMA

Swank, Senussi, Manickas-Hill, Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae, Clin Infect Dis

Trinetx, The global health research network

University, Paxlovid for Treatment of Long Covid

Uo, COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19

Xie, Choi, Al-Aly, Nirmatrelvir and the Risk of Post-Acute Sequelae of COVID-19, medRxiv

DOI record: { "DOI": "10.1101/2023.04.05.23288196", "URL": "http://dx.doi.org/10.1101/2023.04.05.23288196", "abstract": "Background: The role of Nirmatrelvir plus ritonavir (NMV-r) in preventing post-acute sequelae of SARS-CoV-2 infection (PASC) is unknown. The objective of this study is to assess the effect of NMV-r in non-hospitalized, vaccinated patients on the occurrence of PASC. Methods: We performed a comparative retrospective cohort study utilizing data from the TriNetX research network, including vaccinated patients ≥18 years old who subsequently developed Covid-19 between December 2021-April 2022. Cohorts were based on NMV-r administration within five days of diagnosis. Based on previously validated broad and narrow definitions, the main outcome was the presence of symptoms associated with PASC. Outcomes were assessed between 30-180 days and 90-180 days after the index Covid-19 infection. Results 1,004 patients remained in each cohort after propensity-score matching. PASC (broad definition) occurred in 425 patients (42%) in the NMV-r cohort, vs. 480 patients (48%) in the control cohort (OR 0.8 CI 0.67-0.96; p=0.01) from 30-180 days and in 273 patients (27%) in the NMV-r cohort, as compared to 347 patients (35%) in the control cohort (OR 0.707, CI 0.59-0.86; p<0.001) from 90-180 days. Narrowly defined PASC was reported in 337 (34%) patients in the NMV-r and 404 (40%) in the control cohort between 30-180 days (OR=0.75, CI 0.62-0.9, p=0.002) and in 221 (22%) in the NMV-r cohort as compared to in 278 (28%) patients in the control cohort (OR=0.7, CI 0.63-0.9, p=0.003) between 90 -180 days. Conclusions NMV-r treatment in non-hospitalized vaccinated patients with Covid-19 was associated with a reduction in the development of symptoms commonly observed with PASC and healthcare utilization.", "accepted": { "date-parts": [ [ 2023, 4, 6 ] ] }, "author": [ { "affiliation": [], "family": "PATEL", "given": "RUSHIN", "sequence": "first" }, { "ORCID": "http://orcid.org/0000-0002-3434-6136", "affiliation": [], "authenticated-orcid": false, "family": "Dani", "given": "Sourbha S", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-7262-6905", "affiliation": [], "authenticated-orcid": false, "family": "Khadke", "given": "Sumanth", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0001-6828-6154", "affiliation": [], "authenticated-orcid": false, "family": "Ahmad", "given": "Javaria", "sequence": "additional" }, { "affiliation": [], "family": "Shah", "given": "Jui", "sequence": "additional" }, { "affiliation": [], "family": "Mehta", "given": "Neev", "sequence": "additional" }, { "affiliation": [], "family": "Wener", "given": "Kenneth", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0003-4654-4217", "affiliation": [], "authenticated-orcid": false, "family": "McQuillen", "given": "Daniel P", "sequence": "additional" }, { "affiliation": [], "family": "Abraham", "given": "George", "sequence": "additional" }, { "affiliation": [], "family": "Faust", "given": "Jeremy", "sequence": "additional" }, { "affiliation": [], "family": "Maley", "given": "Jason", "sequence": "additional" }, { "affiliation": [], "family": "Patel", "given": "Smita", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-9156-9424", "affiliation": [], "authenticated-orcid": false, "family": "Mullington", "given": "Janet", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0003-3226-2737", "affiliation": [], "authenticated-orcid": false, "family": "Wachter", "given": "Robert", "sequence": "additional" }, { "affiliation": [], "family": "Mosenthal", "given": "Anne", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0001-8434-174X", "affiliation": [], "authenticated-orcid": false, "family": "Sax", "given": "Paul", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0003-0296-6864", "affiliation": [], "authenticated-orcid": false, "family": "Ganatra", "given": "Sarju", "sequence": "additional" } ], "container-title": [], "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2023, 4, 7 ] ], "date-time": "2023-04-07T04:30:14Z", "timestamp": 1680841814000 }, "deposited": { "date-parts": [ [ 2023, 4, 7 ] ], "date-time": "2023-04-07T04:30:14Z", "timestamp": 1680841814000 }, "group-title": "Infectious Diseases (except HIV/AIDS)", "indexed": { "date-parts": [ [ 2023, 4, 8 ] ], "date-time": "2023-04-08T05:03:11Z", "timestamp": 1680930191368 }, "institution": [ { "name": "medRxiv" } ], "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2023, 4, 6 ] ] }, "link": [ { "URL": "https://syndication.highwire.org/content/doi/10.1101/2023.04.05.23288196", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "246", "original-title": [], "posted": { "date-parts": [ [ 2023, 4, 6 ] ] }, "prefix": "10.1101", "published": { "date-parts": [ [ 2023, 4, 6 ] ] }, "publisher": "Cold Spring Harbor Laboratory", "reference-count": 0, "references-count": 0, "relation": {}, "resource": { "primary": { "URL": "http://medrxiv.org/lookup/doi/10.1101/2023.04.05.23288196" } }, "score": 1, "short-title": [], "source": "Crossref", "subtitle": [], "subtype": "preprint", "title": "Incidence of Symptoms Associated with Post-Acute Sequelae of SARS-CoV-2 infection in Non-Hospitalized Vaccinated Patients Receiving Nirmatrelvir-Ritonavir ", "type": "posted-content" }

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0